Revolutionizing Antibacterial Treatments
DeNovaMed champions the fight against the toughest Bacterial Infections Affecting Diabetic and Other Patients
See our Article in Nature Communications
Challenges We Address
The Impact of Diabetic Foot Ulcers (DFUs)
Up to 50 million
Patients per year
globally
80%
Of North American
amputations are due to DFUs
We are addressing these and other serious health issues with our innovative solutions
Cutting-Edge Antibiotic Innovation
-
Broad-Spectrum Antibiotics
-
Targeted DFU Treatment
-
Combating Drug Resistance
-
Advanced Lipid Metabolism Research
-
Biodefense Applications
-
Novel Drugs through Computer-Aided Drug Design
-
Topical & Systemic Formulations
-
Preclinical Candidate Progress
-
Antibiotic Adjuvant Development
New Chemical Entities
200
Years Team Expertise
6
+
Issued Patents
6
Years of Research
5
+
About DeNovaMed
Leading Antibiotic Innovators
A vanguard in pharmaceutical innovation, we specialize in developing groundbreaking antibiotics to combat the toughest bacterial infections and diabetic foot ulcers. Our expertise in microbiology and drug design propels us beyond traditional treatments, delivering novel therapies that promise a healthier future.
Our Technology
Cutting-Edge Science Shaping Tomorrow's Medicine
DeNovaMed DNM0547 Family
This is a lead compound identified as a first-in-class antibiotic from a de novo design campaign of over 750 new chemical entities. DNM0547 demonstrates high skin permeability, which provides high potential for topical treatment in Stage 1 and 2 Diabetic Foot Ulcers (DFUs). A mixture of DNM0547 and colistin is being studied for more advanced DFUs. DNM0547 has shown successful outcomes in several preclinical tests, including against many major multidrug-resistant bacteria. DNM0547 also finds potential use in the treatment of other conditions such as MRSA infections, cellulitis, drug resistant bacterial, ischemic limb and peripheral arterial infections.
DeNovaMed DNM0904 Family
DNM0904 is a novel antibiotic developed by DeNovaMed effective against Gram-positive bacteria (such as MRSA) and Gram-negative bacteria in conjunction with colistin. It has shown to perform exceptionally well versus multi-drug and colistin resistant strains. In tests, we determined the Minimum Inhibitory Concentration (MIC) of DNM 0904 against various Gram-positive strains and DNM0904/colistin for battling E. coli, K. pneumoniae, and A. baumannii. The MIC results were 0.01 – 0.03 in all cases, indicating highly effective performance.
Our ultimate goal is to leverage the strength of stand alone DNM0904 and in combination with colistin to combat rising bacterial resistance and provide relief in terms of global economic loss and prevent potential setbacks in public health and industries. DNM0904 has been optimized for application in complex cases where other existing antibiotics are ineffective, bolstering our medical arsenal’s strength and responsiveness in future health-related crises.
Therapeutic Focus
Diabetic Foot Ulcers
Cellulitis
MRSA Infections
Drug-Resistant Bacterial Infections
Peripheral Arterial Disease Infections
Leprosy
Gram-positive and Negative Infections
Anthrax
